Search results

Hemastatx is committed to bringing innovation to patients with severe and underserved bleeding disorders. Our lead program, HMX-001, is a first-in-class antibody therapy designed to address the root cause of severe bleeding episodes in patients with von Willebrand factor (VWF) disorders.

Preclinical stage biopharmaceutical company, spin off of the European Diabetes Study Center (CeeD), dedicated to developing first-in-class biotherapies against diabetes and metabolic diseases, harvesting the breakthrough potential of the muscle secretome to regulate metabolism, a novel and unexplored approach

Enabling breakthrough medicines achieve the outcomes they were designed for. We unlock the full therapeutic potential of innovative drug candidates through our next-gen nanomedicine delivery platform. We want to establish our biovectors as the universal standard for targeted therapeutic delivery.

RhyGaze is a cutting-edge biotechnology company based in Basel, Switzerland, and Philadelphia, Pa., USA, focused on developing gene therapies for retinal diseases causing blindness and aims to restore vision and transform the lives of patients worldwide.

We are a small CRO providing highly tailored services to customers with clinical trials and regulatory consulting needs. With expertise in drug, food supplements, medical devices, diagnostics and software, we support you at every stage of product's lifecycle, from preclinical development to market.

Opterion Health AG is a privately owned, Swiss based, clinical-stage biotech company developing innovative therapies for peritoneal dialysis (PD).

Asemblis is a Swiss TechBio company developing scalable, human-relevant in vitro models for obesity and metabolic disorders. The company partners with industry and research organizations to support translational R&D and decision-making in drug development

AzureCell is a Swiss regenerative cell therapy company leveraging two decades of pioneering neuroscience and cell‑engineering research at the University of Geneva to advance next‑generation allogeneic cell‑replacement therapies for the brain.

Stallergenes Greer is a fully integrated global healthcare company specialising in the research, diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy (AIT) products and services.

Swiss Rockets is dedicated to developing groundbreaking medicines that transform the treatment of cancer, infectious diseases, and autoimmune disorders – advancing more effective, equitable, and accessible healthcare for patients worldwide.

CALDRE is a Switzerland based biotech spin-out focussed to revolutionize the way cholestatic-and fibrotic diseases are treated. We develop precise, liver-directed GalNAc-siRNAs to restore bile flow and prevent fibrosis - placing CALDRE in the fast-growing RNA-therapeutics segment of biotech.

RC TRITEC is an established company offering custom synthesis of tritium-labeled compounds, a range of tritiated catalog products, storage service and disposal of radiochemicals. We have over 60 years of experience in the safe handling of tritium gas using in-house developed high-vacuum equipment.

SYDRA AG (Zurich) is a longevity biotech using a phenotype-first, AI-assisted “Hit-to-Target” early drug discovery platform. We discover small molecules (geroprotectors), validate in vivo (worms – aged mice), then map MoA to build partner-ready drug assets; plus science-backed supplements.

Topadur Pharma AG, founded in 2015 in Schlieren, is a clinical-stage biopharmaceutical company. Leveraging its proprietary DualTOP™ platform, Topadur develops dual-acting molecules that restore cGMP levels, repairing microcirculation, promoting tissue regeneration, and addressing oxygen deficiency.

Swiss Consultant-Network GmbH is developing a new data management system that can be used as a framework for the integration of heterogeneous data in the field of biological research and development. We offer our customers IT engineers, who have in-depth knowledge of computer science disciplines.

Jantar is a clinical R&D company in the field of chronic rhinosinusitis. Its product is a nasal spray of dicholine succinate. Clinical efficacy has been demonstrated by well-documented case studies which showed that the drug relieves all symptoms of the disease. A PCT patent has been filed.

Mabylon is a clinical-stage company leading innovation in human-derived antibody therapeutics for severe allergies, inflammation, and neurological disorders. MY006, our first-in-class multi-specific antibody therapeutic for peanut allergy, is tackling the growing food allergy market.

Enantios is a Swiss startup revolutionizing molecular characterization with in-solution structural analysis of chiral complex molecules and Antibody drug Conjugates (ADCs). Enantios delivers solutions for quality control and drug development in pharmaceutical, biotech, and chemical industries.

AND Biotech is a science-led company developing bioactive technologies that target the core systems of human resilience. We take promising compounds and translate them into clinically meaningful interventions. We develop scalable technologies that address biological decline, starting long before disease.

Our platform enables efficient, tunable multiplex gene silencing, modulating multiple targets in one construct for superior safety and potency over traditional editing. Its modular design suits various cell and gene engineering applications.

CMC & More delivers hands-on CMC, regulatory, and quality expertise for biotech and pharma. We bridge discovery to first-in-human trials and beyond with GMP-compliant CMC strategies that derisk development and transform complex products into approval-ready assets.

At Lederer & Partner AG, we transform complex visions into clear successful results. Our expertise in engineering, construction, commissioning, qualification, and operation, we develop project models that are precisely aligned with your goals. As your trusted partner, we deliver lean, efficient solutions.

Ultimate Medicine is a Swiss preclinical biotech focused on preserving independence and quality of life for patients with Alzheimer's disease and other dementias.

EVIIVE develops single extracellular vesicle-based diagnostics to predict immunotherapy response and monitor tumor microenvironment in real time. Our platform integrates advanced flow analytics and machine learning for precision oncology applications.

TheraPPI Bioscience, a preclinical biotechnology company developing small molecules modifying protein interactions in oncology, rare diseases and inflammation

The Future Rewritten: Unlocking Genome Editing. By fusing directed evolution, high-throughput characterization, and AI, Nerai creates novel CRISPR editors, more precise and more powerful, making gene editing safer and accessible to more patients.

Tridek-One is a biotech start-up developing first-in-class CD31 agonist modalities designed to restore the immune balance.

Beech Biotech is developing a novel treatment for preeclampsia, an severe unmet medical need that takes the lives of 70,000 women and 500,000 babies each year. The company is developing a novel placenta-impermeable antibody and works with a network of expert industry consultants and contractors.

XEMPERIA, a spin-off from the University of Fribourg, is pioneering a groundbreaking approach to blood testing that leverages the body's immune response to detect breast cancer at its earliest and most treatable stage.

Umlaut.bio develops first-in-biology small molecules focusing on tRNAs that protect signalling transduction mRNAs from degradation. Addressing this previously undrugged fundamental biochemical principle  could be able to selectively prevent the growth of cancer as well as  proinflammatory cells.

Parithera is pioneering an AI-ready, clinical-grade liquid biopsy platform for single-cell analysis. Our platform is ideally positioned to study cancer treatment resistance.

MicThera harnesses microbes to discover breakthrough therapeutics, leveraging microbial bioactive molecules -synthetically produced- to overcome therapy resistance. Our discovery platform unlocks microbial-inspired therapeutics to develop innovative treatments.

SPILLO supports pharmaceutical and biotech R&D teams through unbiased, in silico, proteome-wide identification of targets and off-targets. Using exclusive, experimentally validated, physics-based computational technology, SPILLO reduces scientific risk and clarifies mechanisms in drug development.

Devintec Pharma is focused on B2B partnerships through out-licensing innovative substance-based medical devices. We apply DevinPro™ technology, that addresses root causes and creates a protective barrier for lasting relief, to our patended products in gastroenterology, dermatology, and gynecology.

Cure Pharma specializes in clinical supply management, including global supply chain coordination, comparator sourcing, logistics, and innovative labelling solutions. With a strong network and regulatory expertise, we ensure efficient, compliant, and reliable supply solutions for clinical studies.

A swiss-based company developing therapeutics for chronic inflammation. We are engineering novel bi-functional Duokine therapeutics, rationally designed to simultaneously target distinct immune cell populations and disease-relevant pathways.

Nxera Pharma is a tech-driven biopharma company focused on specialty medicines for unmet needs in Japan and globally. With 30+ active programs in neurology, GI, immunology, metabolic, and rare diseases, Nxera employs 350+ people across Japan, the UK, Switzerland, and South Korea.

Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients.

TransHeps specializes in iDILI causality assessments, supporting drug developers in clinical trials and managing drug-induced liver injuries. Leveraging cutting-edge expertise, we provide reliable solutions to improve drug safety and accelerate pharmaceutical innovations.

Our single-use bioreactor simplifies and accelerates cell culture with automation and closed systems, accommodating volumes from 30 mL up to 30 L in the same vessel. Designed for a broad range of cells and for the entire product lifecycle (clinical research, process development, manufacturing).

Genevant brings world-class delivery platforms that include best-in-class lipid nanoparticle (LNP) technology and next generation ligand conjugate technology, the industry’s most robust and expansive LNP patent estate, decades of experience and expertise in nucleic acid drug development.

metaLead is an early-stage life science spinout from the University of Zurich, supported by reputable investors, i.e., BaseLaunch. We aim to revolutionize the treatment landscape for metal-related diseases, starting with Wilson disease, leveraging our platform of novel, rationally designed peptides.

Leman Biotech is a clinical-stage biotech advancing immunotherapy via metabolic reprogramming. Its META 10 platform reverses T-cell exhaustion to unlock unprecedented efficacy and durability in oncology and autoimmune diseases, delivering a highly effective, scalable, and accessible approach.

dEEGtal develops AI-driven solutions to enhance EEG analysis, starting with a medical device for epilepsy diagnosis. While focused on clinical applications, we are expanding to offer AI models that provide deeper insights into EEG data for neuroscience, pharma, and industry partners.

Philip Morris International (PMI) is a leading international tobacco company with the objective to replace cigarettes with smoke-free products. The goal is to offer adult smokers, who would otherwise continue to smoke, better alternatives that are scientifically substantiated.

Neurosterix is a biopharmaceutical company focused on developing allosteric modulators for the treatment of neurological disorders. Our drug discovery and development platform identifies and develops allosteric modulators.

Abbmira therapeutics is a Basel based biotech founded by experience scientists and entrepreneurs in September 2024. Abbmira develops first-in-class small molecules to fine-tune native immunity to treat difficult-to-treat cancers and chronic diseases.

We "think data" and "speak biology", partnering with our clients to transform lives. Our team combines deep biological knowledge with proven expertise in AI & bioinformatics to tackle complex data challenges. Via our AI-native Bio|Verse platform, we accelerate biomarker discovery & drug development.

At CxO, we drive biotech startups toward growth by optimizing resource management and operational efficiency. As partners, we empower firms to innovate and scale. Our veteran team offers strategic insights to accelerate timelines, optimize ROI, and enhance workflows, ensuring client success

InVirtuoLabs is pioneering the next-generation laboratory by integrating AI with molecular simulations to revolutionize drug discovery. Our platform generates up to 1 billion novel molecules per day, rapidly screening and identifying the most promising ligands for specific biological targets.

Avenza Consulting has been created to support pharma, biotech companies, startups to develop and grow by offering Strategic Consulting, R&D services to foster innovation, Program & Portfolio Management to optimize projects, and Operational Excellence to streamline processes.

Signal26 Biotherapeutics is a biotechnology startup dedicated to advancing a novel antibody for treating psoriasis. In collaboration with interdisciplinary experts, we lead research into interleukin 26 (IL-26) and its role in the signalling pathways involved in autoimmune disorders.

Precise Health develops AI-powered platforms for bacteriophage discovery, host-matching, and engineering. We serve hospitals, biotech, and pharma in the $50B+ anti-infectives and diagnostics markets, addressing the urgent global threat of antimicrobial resistance

Juvion develops advanced therapeutics aimed at preserving neuron-muscle connectivity, tackling immobility and sarcopenia to extend healthspan.

We provide a portfolio of models for efficacy pharmacology in autoimmunity, immuno-oncology, and transplantation. Our humanized mouse and tumor xenograft platforms enable translational evaluation of biologics, cell therapies, and innovative immunotherapies.

Release Therapeutics is a preclinical-stage BioMedTech company developing the first cell macroencapsulation technology specifically designed to get therapeutic proteins where they are needed most, in the CNS and beyond.

Enzene is a fully integrated CIDMO with sites in Pune (India) & New Jersey (USA), offering discovery to commercial supply. Its EnzeneX™ FCCM™ tech leads next-gen biologics, aiming to cut mAb costs below $40/g by 2025. Learn more at www.enzene.com.

BeOne Medicines is a global oncology company developing innovative, affordable, and accessible cancer treatments worldwide. We expedite development of our diverse pipeline of novel therapeutics through strong internal capabilities and collaborations. Our 11,000 colleagues span six continents.

Skyvor Medical develops AI-powered digital platforms (RecruitNavigator, ATOM EDC) to  accelerate the feasibility (protocol, site optimizations) and the data collection in clinical trials. Together with our data management services, we offer a turnkey solution for managing clinical trial data.

Founded in mid-2022, T-Oncology is a Swiss biotech startup dedicated to transforming cancer treatment through innovative therapies. Our Mission: Give hope to patients by creating advanced therapeutics that offer safe and more effective treatment options, affordable for patients worldwide.

Amporin is developing a new class of small molecule amyloid pore inhibitors as the first potential acute oral drugs to stop and reverse the progression of deadly degenerative diseases. Our vision is to cure 6 major degenerative diseases with a simple pill, starting with Parkinson’s disease.

Procavea Biotech is an ETH Spin-off company developing an innovative protein-based RNA delivery platform. Our focus is to generate siRNA therapeutics in extrahepatic disease areas that are currently unreachable.

Prasfarma is a Pharmaceutical Company that operates as a CMO and CDMO) with experience in cytostatics, high potency products and biologics. Our flexibility & state of the art technologies, make us the ideal partner for small productions or R&D projects (pilot plant) and commercial supply (factory).

Chelonia collaborates with industry, academia, and public institutions to accelerate R&D, commercialize innovations, and secure funding. We offer strategic partnerships, expert guidance, and project support to maximize impact.

Allegria Therapeutics was founded in Basel in 2023. Pursuing a differentiated portfolio of proprietary therapeutic approaches around biological targets that selectively modulate mast cells, Allegria plans to redefine the treatment landscape for allergy and mast cell-mediated inflammatory diseases.

Complyomics supports Life Sciences companies in core areas as: Build and maintain robust Quality Systems in compliance with regulatory requirements. Provide externalized QA. Audits Develop expertise in Bioanalytical / Analytical areas Identify / assess / supervise sub-contractors Due diligence

Tandem Therapeutics (Spin-off ETH Zurich & PSI) is tackling the growing unmet medical need in treating fibrosis with precision extracellular matrix targeting. Our novel peptide drug conjugates selectively target mechanical changes in the fibrotic extracellular matrix to potentially halt progression.

ARTBIO is a clinical-stage radiopharmaceutical company focused on developing a new class of alpha radioligand therapies (ARTs) to transform cancer treatment. ARTBIO's approach centers on utilizing the alpha-emitting isotope Pb212 to target cancer cells while minimizing damage to healthy tissues.

NanThermix SA is a pioneer in nanoscale temperature control within living cells for applications across life sciences, from academic research to biomedical fields, based on a novel technollogy of all-optical nanodiamond heater / thermometer.

HekeTiss, a UNIGE/HUG spin-off, enhances lives by pioneering cell-therapy treatments for ulcerative skin conditions. Innovating for a healthier tomorrow.

FatiAbGen International is the Swiss subsidiary of FatiAbGen Co. Ltd., established in Korea in 2020. We engineer best in class antibodies tailored for multiple modalities such as ADCs and bi-specifics. We then develop targeted molecules to address high unmet need diseases in oncology and immunology.

NewBiologix is a company developing a proprietary and breakthrough platform for the advanced engineering of cell lines. The company is committed to improving the production of viral vectors used in gene therapy by combining an innovative bioinformatics platform with advanced R&D experimentation.

APR Applied Pharma Research s.a. (wholly owned by Relief Therapeutics Holding AG, SIX: RLF.SW), is a B2B Swiss-based international biopharma focused on development and global commercialization of innovative, patent protected products designed to address unmet needs.

At Stämm we develop accessible, plug & play biomanufacture solutions; allowing an automatized, continuous and more efficient production of biologics and cell therapies while managing media conditions. We have reinvented biomanufacturing by providing an alternative to the known biomass production.

Quant Biomarkers aims to revolutionize cardio-renal and metabolic health with AI-driven solutions and novel biomarkers. We are at the forefront of precision medicine and our goal is to integrate our products into routine clinical workflows spanning primary and speciality care and clinical trials.

Solvias is a Contract Research, Development & Manufacturing Organization We offer comprehensive, high quality and fast, complex small molecule API early phase development and GMP-manufacturing by ensuring the interplay of scientifically outstanding experts in every required individual discipline.

At ATANIS Biotech AG, our mission is to revolutionize the way allergies are diagnosed and thereby to improve treatment success Our novel cell-based assay allows us to quantify patients allergic status with unparalleled diagnostic accuracy, without needing to expose patients to the culprit allergen.

Salvina Therapeutics is developing antibodies with a novel approach for targeting TNF and TNF superfamily members with the aim of improving their safety and efficacy, and facilitating the generation of novel bispecific therapies.

Oryl Photonics has developed a groundbreaking laboratory instrument for solubility and aggregation measurement. It is the world's first accurate and rapid solubility testing solution that saves precious drug compounds.

ONtrack Biomedical AG is a Swiss spin-off of the University Zurich and University Hospital Zurich which develops in-vitro diagnostic tests for the early and non-invasive detection and monitoring of cancer. Our first product is a urine test for the early detection and monitoring of prostate cancer.

FinalSpark is at the forefront of technological innovation, pioneering the development of bioprocessors — the next generation of digital processors. These groundbreaking bioprocessors utilize human neurons instead of traditional silicon, marking a significant leap in processing technology.

iCure offers the Cardinal platform for developing digital health applications that comply with cybersecurity standards, with end-to-end encryption, FHIR interoperability, and open-source SDKs, accelerating innovation in e-health. iCure is ISO27001,ISO13485,HDS certified and GDPR and NIS2 compliant.

RDP Pharma (RDP) is a privately held biotech, dedicated to the vision that their products will deliver valuable medicines to patients in need. RDP’s leadership team and board of directors are focused on getting their products into clinical trials and addressing the unmet medical needs of patients.

Altorfer Engineering is a specialized contractor and consulting company. We provide expertise in engineering and project management services, and technology transfers. Our focus is on developing and managing aseptic formulation and fill-finish processes tailored to your receiving sites.

Olgram develops new drugs to cure immune deficiencies for which there are no satisfactory therapeutic solutions. Our 1st clinical application is immunodepression post traumatic brain injury, affecting 5 million people. We also develop new anti-infectious to cure the chronic bacterial infection.

inSEIT solves the challenges of enzyme immobilization and unlocks the potential of immobilized biocatalysts for the production of APIs and chemical intermediates. We use bioinformatic tools to reduce the risk, time and cost associated with biocatalyst development.

Revolutionizing clinical trials, Trialize's cutting-edge automation platform accelerates study build times by 4x and curbs manual labor by up to 73%, enhancing data quality, patient adherence, and team morale. It's a game-changer in modern, decentralized, and virtual studies.

CELLnTEC technologies enable science and industry to develop innovations in stem cell research, regenerative medicine, cell-based therapies, and beyond. The company is a pioneering developer of chemically defined, animal and human components-free precision media.

Caland SA provides a professional, confidential, competitive and impeccable service of pharma-grade CO2 extraction, distillation and cannabis formulation based on GMP requirements. A modern production line, coupled to a qualified ERP, ensures uncompromising quality of all products and services.

We at INCAPTEK are developing advanced drug delivery systems. We deliver drugs at the right place, in the right dosage, and at the right time. Our smart, programmed-shell micro(nano)capsules can be used for controlled and targeted drug delivery for both biotech and medtech.

Curare specializes in translational and clinical pharmacology, increasing confidence in therapeutics translation from the bench to clinical proof of concept, and enhancing early stage decision-making.Expertise tailored to your needs, from small biotech to pharma.

Our goal is to deliver innovations in health care through cutting-edge tech and research, addressing challenges in antimicrobial therapies to improve patient outcomes. We are committed to delivering superior treatments that promote healing and improve quality of life globally.

Rambam AG is a Swiss-based venture studio and accelerator platform for breakthrough drug discovery and development. Our portfolio of companies and programs is supported by a core group of seasoned industrial experts, PMs and dedicated functional experts from Switzerland, Portugal, Germany and the US.

Floratek Pharma is focused on drug discovery and preclinical development, enhancing the healing power of plants through the optimisation of existing natural compounds. The company pipeline comprises of anti-cancer and neurodegenerative disorder therapies as well as anti-aging dietary enhancements.

I work WITH my clients as a freelance science business development project manager. Having said that, Boehler Life Science Advice is not typical consultancy, even though strategic planning and execution is an important part of supporting my clients.

We are a clinical research team delivering patient-centric clinical investigations across Europe and MENA. We combine strong site access with DCT/hybrid delivery, an integrated digital trial stack (eTMF, eCRF, eCOA, RTSM), and risk-based monitoring to start fast, run clean, and stay audit-ready.

Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are unlocking the potential of glycomics and metabolomics in disease biomarker discovery and for the development of safer nutritional and pharmaceutical products.

Orio Therapeutics developed a technology based on protein engineering allowing to integrate a "built-in" delivery systems into any therapeutic protein. Orio Therapeutics has set as a priority for their first product the development of a cardioprotective drug for heart attack patients.

VACCENTIS AG is a Zurich-based investment company focused on the biotech and pharmaceutical sector. The entire research, production and sales activities are carried out by two highly specialized subsidiaries, VCC MEDICAL and FBM- Pharma, which focus on special methods of personalized medicine

InkVivo Technologies combines its patented biomaterial platform with advanced manufacturing technologies to fabricate novel delivery systems that ensure controlled and prolonged release of active ingredients (e.g., small molecules, biologics and micronutrients).

On demand Outsourcing & Supply Chain Experts and Solutions for Innovative Biotechs & Medtechs. Kisco gives access to teams of seasoned experts to support your development cycle, from Preclinical to Clinical Research (CRO), Supply Chain set up, outsourced Manufacturing (CDMO), and R&D Operations.

FimmCyte is developing disease modifying therapies for chronic diseases through the direct elimination of diseased cells. FimmCyte has a pipeline of assets two of which are about to begin IND enabling studies, one for endometriosis and the second for organ fibrosis.

Phialogics is a preclinical biotech company specialized in engineering next-generation biologics to rebalance the immune response in acute and chronic inflammation.

Tenpoint Therapeutics is a global, clinical-stage biotech company developing treatments to rejuvenate vision in the aging eye. Its pipeline includes treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts and geographic atrophy.

Amphilix AG is a Basel-based biotech developing next-generation radioligand therapies using a proprietary 3D linker platform and small-molecule ligands. Its clinical-stage lead AMX-0053 targets a protein for colorectal cancer and is ready for First-in-Human imaging. The company seeks CHF 9m Seed.

Oncodesign Services is a leading CRO specializing in drug discovery and preclinical services in (immuno-)oncology, autoimmune, inflammation and infectious diseases, through integrated capabilities in medicinal chemistry, DMPK, pharmaco-imaging, bioanalysis, and in vitro/in vivo pharmacology.

Cetacea Clinical offers Clinical Operations Services and functional services, including trial management, regulatory compliance, data management, and quality oversight. Our robust Quality Management System ensures efficient, high-quality clinical trials from start to finish.

We identified a novel immuno-oncology target through bacterial metabolites that activate tumor-residing macrophages, triggering a potent anti-tumor response. By leveraging natural metabolic processes, we develop small molecule therapies to enhance the body’s native immune defense against cancer.

ACM Biosciences AG is a subsidiary of ACM Biolabs PTE Ltd. Singapore. Its purpose is to internationalise its development activities. It leads all clinical and regulatory activities of its pipeline programs and coordinates business development discussions with potential partners.

Cellerys AG is a clinical stage biotechnology company, developing immune tolerance therapeutics for the treatment of multiple sclerosis (MS). Antigenic peptides identified from MS patients are coupled to autologous red blood cells which, when reinfused, restore immune tolerance. in 2021 the company entered a

Yokogawa Electric Corporation is an automation company for the manufacturing industry based on measurement, control, and information technologies. Yokogawa Innovation Switzerland is its subsidiary, and its dedicated mission is R&D in the bioeconomy field based on open innovation.

We are an independent Biotech company based in Ticino. We focus on generation, development and characterization of nanobodies produced from proprietary, rationally engineered human libraries relevant to enhance the R&D pipeline of partners and clients.

Alloy Therapeutics is a biotechnology ecosystem company democratizing access to tools, technologies, and services for discovering and developing therapeutic biologics across six modalities, including antibodies, TCRs, genetic medicines, peptides, cell therapy, and drug delivery.

NexMR offers the first technological solutions to do drug discovery on a benchtop NMR spectrometer without compromising speed and data quality.

AlphaMol is an AI-based bio-pharmaceutical company focusing on G protein-coupled receptor drug discovery. The Cofounders of AlphaMol are leading scientists in the area of GPCRs. Many essential molecular mechanisms and biotechnology were invented by the members of AlphaMol.

PDC Therapeutics is a clinical-stage biotech start-up developing targeted Polymer-Drug Conjugate technologies with an optimal therapeutic index. The proprietary Sagitta® biodegradable conjugation platforms help discover and develop therapies with no compromise with a versatile targeting capability.

Pheida develops and deploys biotech solutions at scale to reduce GHG emissions and other pollutants, and to remediate contaminated soil and water. Pheida products combine advanced biotech, proprietary application engineering to deliver unique and commercially attractive solutions.

Founded in 2018, Peptone specializes in novel therapeutics for Intrinsically Disordered Proteins (IDPs), linked to inflammatory diseases such as cancer. Their approach integrates biophysics, supercomputing, and machine learning, now advancing in their labs.

SEAL Therapeutics develops an innovative gene therapy approach that overcomes the functional defects causing LAMA2-related muscular dystrophy. The approach involves AAV-based delivery of specifically designed artificial linker proteins to compensate for the missing laminin-alpha 2 in muscle fibers.

Thermo Fisher Scientific Lengnau is a state-of-the-art multi-purpose manufacturing facility for the production of biologics. It offers highly flexible biomanufacturing technologies, from development to large-scale production with single use and stainless steel equipment to meet our customer needs.

Whatever your level of maturity regarding the valorization of data in your company, our Luciders are your trusted advisors to design and implement a data roadmap. We will work closely with your different business units to explore how data, advanced analytics, AI and ML can solve complex challenges.

Tigen is a Swiss clinical stage biotech company developing cell therapies to cure cancer. A disruptive catalyst, combining a unique culture with a multidisciplinary set of world-class capabilities and a long-term perspective to accelerate access to novel T-cell therapies for patients and society.

MedXCell is a Swiss biotech venture builder led by entrepreneurs and backed by private investors. MedXCell's portfolio includes pre-clinical companies CYTEA BIO and Soteria Bio.

Solid Drug Development (SDD) is a Strategic and Operational consultancy based in Geneva. The company founded in 2010 is specialized in the development of Biotech and Pharma products.

Real-Time Immunoassays: Quantitative, Fast (10min to result), Simple (one step) using Disposables

MPC Therapeutics is the leading biotech company developing Mitochondrial Pyruvate Carrier (MPC) targeted therapies. MPC is an extraordinary target that plays a key role in metabolism. We are committed to delivering novel treatments in cancer immunotherapy, kidney diseases and neurodegeneration.

We are a clinical-stage biotech company developing first-in-class small molecules to induce mitophagy, i.e. the process of replacing damaged mitochondria. We address age-related and chronic diseases including CNS disorders to treat cognitive impairment..

4bases is a company active in the fields of prevention and precision medicine. 4bases is a certified company working accordingly to the IVDR regulation. Our products are reagent kits for platform-independent New Generation DNA Sequencing (NGS), data analysis software and diagnostic protocols.

Somagenetix is a spin-off from the University of Zurich leveraging scientific, clinical & commercial expertise to solve unmet medical needs. With our gene therapy platform, we aim at becoming a leading company with first & best-in-class treatments for phagocyte-related disorders.

Mosanna is committed to improving patient outcomes and quality of life in high unmet need diseases, carefully selecting innovative medicines for further development. Our first goal is to bring an effective and well tolerated medicinal nasal spray to Metabolic Obstructive Sleep Apnea patients.

Adoram Therapeutics is developing a suite of small molecule allosteric modulators for different indications. Our primary asset in the preclinical stage, is a negative allosteric modulator (NAM) of a clinically validated immuno-oncology target - the adenosine 2A receptor (A2AR).

Aukera builds a discovery engine that allows designing new classes of drugs to selectively target different branches of the mTOR pathway. The lead program selectively targets mTOR complex 1 to treat rare diseases, cancer, and neurodegenerative diseases, and uniquely addresses unmet medical needs.

FluoSphera has developed human multi-tissue systems that accurately replicate and analyze how a drug interacts with multiple organs to predict systemic response in humans, i.e. the response at the whole body level — ultimately determining clinical success for patients.

Praed Pharmaceuticals is biopharmaceutical company founded by industry experts. Our mission is to deliver a next generation treatment for Crohn’s disease. We are developing a promising oral compound, cadazolid, for the treatment of Crohn’s disease.

Streefkerk Life Science Consultancy (SLSC) supports small pharmaceutical companies to improve efficiency, comply with regulations and standards, and excel in designing high-quality clinical development plans, to deliver new drugs to patients as soon as safely possible.

Aspeya, owned by Philip Morris International, operates independently and utilizes Fertin Pharma's oral technology platform. Fertin Pharma, a wholly owned subsidiary of Aspeya, is a CDMO that develops and manufactures innovative oral and intra-oral delivery systems.

Biotech in the Autoimmune/Fibrosis Therapeutics Space.

Ymmunobio AG is a preclinical stage biotechnology company developing first in class assets for the treatment of solid tumors.

House of Lab Science is the ultimate destination for serviced laboratory space across Switzerland. We believe that lab space should be ready-to-move in, affordable, certified & well equipped. Our lab-as-a-service model is designed to help you advance your research and business from day one.

Aurealis Therapeutics is a Swiss-Finnish Cell and Gene Therapy Platform Company. Our multi-target scalable low COGS products, based on genetically engineered lactic acid bacteria, addresses unmet medical needs: Chronic Wounds - Diabetic Foot Ulcers, Venous Ulcers - Cancers - Ovarian, Peritoneal

Based in Epalinges, Pilatus Biosciences focuses on developing a first-in-class antibody targeting metabolic checkpoints. The company is transforming cancer treatment by developing innovative therapies that strengthen the immune system to fight cancer.

Atopia Therapeutics is developing a revolutionary treatment for allergic diseases such as atopic dermatitis, allergic asthma, food allergies and hay fever based on the discovery that a bacterium present in the human stomach produces a protein that protects us from these diseases.

MD Bioproducts, with over 30 years of experience, is a worldwide manufacturer and supplier of high-quality antibodies, reagents, peptides, assays, and disease-induction reagents supporting research in arthritis, autoimmune diseases, immunology, inflammation, neurology, metabolism, and oncology.

Immune response on a chip!

NovaGo Therapeutics focuses on two regeneration promoting therapeutics aimed at restoring nerve fibre connections in acute spinal cord injury(SCI) and retinal vasculature in diabetic retinopathy(DR), Ph1b clinical trial for SCI was started in Dec 2024. Ph1b studies in DR are planned for end 2025.

NXI Therapeutics is committed to creating tomorrow’s disruptive immunotherapies for T cell-mediated autoimmune diseases and transplantation by coronin 1 modulation. NXI’s unique approach enables an auto- & allo-selective immunomodulation that retains immunocompetence against infections and cancer.

ZETA is an end-to-end solution provider and innovation leader for pharma & biotech and specializes in the design, automation, and qualification of customer-specific systems for pharmaceutical manufacturing. ZETA is an EPCMv contractor, drives digtialization and develops decarbonization strategies.

TissueLabs is a Swiss biotech pioneering biofabrication, developing 3D bioprinters, tissue-specific hydrogels, and engineered tissues. Supporting research, drug testing, and regenerative medicine, its long-term vision is to create the first transplantable bioartificial heart.

InCephalo is a preclinical stage biotech company with a compartment locked (CLocked) technology. InCephalo is positioning itself as a CLocked Fc-Fusion Cytokine and antibody company. The company’s most advanced product at a proprietary IL-12 for local application of brain cancers.

therainnova AG provides strategic and operational regulatory affairs consulting for the biopharmaceutical industry in Europe. With expert leadership and a strong partner network, we offer end-to-end regulatory support, including due diligence, to maximize portfolio value.

Limula is a Life Science Tools company based in Lausanne, Switzerland. We combine cell therapy process development and precision engineering to offer a fully closed and automated platform for the production of CAR-T and other highly-personalised treatments.

Healiva’s Wound Care & Skin Diseases proprietary Platform Technology includes an end-to-end approach with enzyme technology and cell therapies for wound care and skin diseases. The platform can diversify into vitiligo management, skin regeneration or sports injury applications.